摘要
目的:系统评价痰热清注射液治疗慢性阻塞性肺疾病急性加重期的疗效及安全性。方法:计算机检索Pub Med、EMbase、Cochrane图书馆、VIP、CNKI、CBM和万方等数据库(检索时限均从建库至2016年5月),纳入痰热清注射液治疗慢性阻塞性肺疾病急性加重期的随机对照试验。评价纳入研究的方法学质量和提取有效数据后,采用Rev Man 5.3软件进行Meta分析。结果:共纳入39个RCT,3 685例慢性阻塞性肺疾病急性加重期患者。Meta分析结果显示:痰热清注射液组的临床总有效率高于对照组(RR=1.15,95%CI[1.12,1.18],P<0.000 01),能够提高AECOPD患者的第1秒用力呼气容积(MD=0.27,95%CI[0.21,0.34],P=0.000 2),第1秒用力呼气容积(FEV1)与用力肺活量(FVC)的百分比(MD=8.04,95%CI[5.87,10.22],P<0.000 01)和动脉血氧分压(SMD=0.83,95%CI[0.60,1.07],P<0.000 01),能够降低AECOPD患者的动脉血二氧化碳分压(SMD=-0.75,95%CI[-1.04,-0.47],P<0.000 01)。研究中无严重不良事件报告,安全性较高。结论:现有临床证据表明,在常规治疗的基础上加用痰热清注射液能够提高治疗慢性阻塞性肺疾病急性加重期的临床疗效。但由于现有研究的样本量小、方法学质量低,上述结论还需要开展大样本、高质量的随机对照试验加以验证。
Objective： To systemically evaluate the efficacy and safety of Tanreqing injection on acute exacerbations of chronic obstructive pulmonary disease（ AECOPD）. Methods： The computer retrieval of Pub Med,EMbase,Cochrane Library,VIP,CNKI,CBM and Wan Fang etc. database（ from the date of database establishment to May2016） were conducted,and brought in controlled randomized trials（ CRT） of Tanreqing injection for AECOPD. After the methodological quality of included researches was evaluated and the valid data were extracted,the Meta analysis was made by Cochrane Collaboration＇s Rev Man 5. 3 software. Results： 39 CRT with 3685 patient with AECOPD were included in total. The results of meta- analysis showed that the Tanreqing injection group was better than the control group in total effective rate（ RR = 1. 15,95% CI[1. 12,1. 18],P〈0. 000 01）,and the Tanreqing injection could enhance AECOPD patients＇ FEV1（ MD = 0. 27,95% CI [0. 21,0. 34 ],P = 0. 000 2）,FEV1 /FVC%（ MD = 8. 04,95% CI[5. 87,10. 22 ],P〈0. 000 01）,Pa O2（ SMD = 0. 83,95% CI [0. 60,1. 07],P〈0. 00001） and reduce AECOPD patients＇ Pa CO2（ SMD =- 0. 75,95% CI [- 1. 04,- 0. 47],P〈0. 000 01）. In researches,no serious adverse events were reported,and the security was higher. Conclusion： The current clinical evidences have shown that Tanreqing injection combined with conventional therapy can improve the clinical effect on AECOPD. But because of the small sample size and the low methodological quality of existing researches,the above conclusion has need to be verified further by CRT of large- scale samples and high quality.
出处
《山西中医》
2016年第10期11-18,共8页
Shanxi Journal of Traditional Chinese Medicine
关键词
痰热清注射液
慢性阻塞性肺疾病
随机对照试验
系统评价
Tanreqing injection
chronic obstructive pulmonary disease
controlled randomized trials
systemic evaluation
